Data cutoff: October 29, 2026, 8:30 p.m. ET. Latest completed U.S. equity trading session: Thursday, October 29, 2026. Lilly published Q3 results before the regular U.S. session and held its call at 10:00 a.m. ET.
The obesity-drug leader's growth is now a question of volume, price and access
Eli Lilly released its third-quarter 2026 earnings on October 29, reporting a 39% rise in revenue to approximately $24.4 billion. The company simultaneously lifted the midpoint of its full-year sales outlook by $5.5 billion. The figures arrived against a more complex environment for diabetes and obesity medicines: prescriptions are expanding, insurers and public programs increasingly influence access, and realized selling prices are under pressure. Lilly's results matter far beyond one pharmaceutical stock because investors use them to assess the size, profitability and competitive intensity of a global cardiometabolic-drug market.
The earnings release is a new event, not simply the earlier discussion of next-generation obesity treatments. A trial announcement can inform a possible future product; a quarterly earnings report shows what customers, distributors and payers actually purchased during a defined accounting period. The combination of strong volume and lower prices gives a more nuanced account than either an enthusiastic drug-demand headline or a pessimistic pricing headline alone.
A detailed look at the quarter
Lilly reported third-quarter revenue of $24.397 billion, versus $17.601 billion a year earlier, an increase of 39%. GAAP net income was $6.451 billion compared with $5.583 billion, while reported diluted earnings per share rose 16% to $7.22. Non-GAAP diluted EPS was $7.48, up 7% from $7.02. These two EPS measures are separate and neither should be labeled a cash-flow measure.
The comparison contained material accounting and business-development effects. Lilly said Q3 reported and non-GAAP EPS each included $4.57 of acquired in-process research-and-development charges per share, versus $0.71 in the comparable quarter of 2025. This is particularly important because a reader might otherwise assume that the adjusted earnings figure excludes all acquired R&D. The disclosure shows that assumption would be wrong. Analysts should examine both underlying product economics and the costs associated with expanding the pipeline.
Lilly said global volume rose 53%, partly offset by a 15% decline in realized prices. In the United States, revenue rose 34% to $15.1 billion, supported by a 41% increase in volume and a 7% price decrease. Outside the U.S., revenue climbed 47% to $9.3 billion while volume grew 76% and realized prices fell 29%. These figures show that distribution and patient access can enlarge the revenue base despite lower average prices. They also warn against assuming that today’s volume growth translates mechanically into proportionate growth in profit per prescription.
Mounjaro and Zepbound remained the most visible growth products. Lilly's product-level table reported Mounjaro sales of $10.723 billion, up 65%, and Zepbound sales of $5.352 billion, up 49%. These audited-period product figures are distinct from consolidated profit. The company separately reported $17.1 billion of revenue from its defined key-product portfolio, which includes these medicines and other therapies. Product revenue must not be added to that portfolio figure a second time. Together, the medicines make product concentration and competitive responses central valuation questions.
Higher guidance, but a different EPS story
Lilly raised its full-year 2026 revenue guidance to a range of $91.0 billion–$92.0 billion, an increase of $5.5 billion at the midpoint. The company also described higher underlying non-GAAP earnings expectations. Yet acquired IPR&D charges related to business-development activity affected the reported adjusted-EPS outlook, which was updated to $35.00–$36.00 for 2026. Investors should not interpret a higher sales guide and a changed EPS guide as inconsistent without accounting for the acquired-research charges.
Gross margin was 83.9% of revenue in the quarter, up one percentage point year over year. Research and development expense increased 23% to approximately $4.2 billion, while marketing, selling and administrative expense grew 14% to $3.1 billion. A high gross margin supports the ability to fund clinical trials and manufacturing expansions, but it is not the same as an equally high operating or net profit margin. Launch costs, clinical failures, pricing concessions and acquisitions all sit below gross profit.
Pipeline progress and the limits of early evidence
Lilly highlighted several regulatory approvals and clinical milestones, including new or expanded U.S. indications for existing products and a positive topline head-to-head Phase 3 result involving retatrutide and Ozempic 2 mg in adults with type 2 diabetes. A positive clinical result is not equivalent to an FDA approval for a new medicine or indication. Safety review, submission, manufacturing readiness and labeling remain distinct steps. The same caution applies to earlier-stage programs that management expects to advance into Phase 3.
The company also referenced acquisitions and partnerships designed to broaden the pipeline, including completed business-development transactions. Such spending can diversify future revenue, but acquired intellectual property and research are expensive and may not create commercially successful drugs. The resulting charge should be visible in earnings analysis rather than dismissed as a one-time annoyance every quarter.
The market debate: demand versus sustainable pricing
A constructive view is that higher volumes, international launches, manufacturing investment and new formulations allow Lilly to grow through price competition. Strong Q3 results support the claim that patient demand is real. A more cautious view points to pricing pressure, competition from other incretin therapies, changing insurance reimbursement and the uncertain commercial economics of new oral treatments. Both views acknowledge a large and growing market; they disagree over how much of the future revenue will be retained as durable cash profits.
Share-price gains reported on October 29 are consistent with investor enthusiasm about earnings and guidance, but they cannot isolate drug sales as the only causal factor. Broader market rotations, rates and prior expectations also influence the trading day. Comparisons between Lilly and Novo Nordisk should account for differing indication mixes, geographies, distribution models and drug portfolios.
What to watch next
Lilly did not provide a firm date for its following quarterly earnings announcement in the materials reviewed. Investors can track prescription volume, realized net prices, payer coverage, manufacturing capacity, drug-supply availability, regulatory filings and the timing of additional clinical data. A credible growth analysis should update those signals as they are officially disclosed, without assuming that a future trial, FDA decision or launch occurs on a guessed date. The November 6 U.S. employment report and November 25 consumption-inflation release are confirmed macro dates that may affect market valuation, not Lilly-specific regulatory catalysts.
Conclusion
Lilly's third quarter demonstrates the commercial strength of Mounjaro and Zepbound while showing why an expanding market is not the same as unlimited pricing power. Revenue growth of 39% and raised sales guidance support an ambitious growth case. Falling realized prices, heavy research investment and acquisition charges complicate the earnings path. The company’s next challenge is to convert broadening patient access and an advancing pipeline into durable returns without allowing pricing or development costs to absorb too much of the growth.